- Home
- ANVS vs TVGN Comparison
ANVS vs TVGN Comparison
Compare ANVS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | TVGN |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 89.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | TVGN |
|---|---|---|
| Price | $3.66 | $0.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.50 | $5.00 |
| AVG Volume (30 Days) | 979.7K | ★ 1.4M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.36 |
| 52 Week High | $5.60 | $1.92 |
Technical Indicators
Market Signals| Indicator | ANVS | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 43.20 |
| Support Level | $3.46 | $0.37 |
| Resistance Level | $4.04 | $0.40 |
| Average True Range (ATR) | 0.36 | 0.03 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 15.43 | 32.47 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.